CERC Data Due Dec., SAMURAI Brings Cheer To CLCD, TNXP Slumps As Study Fails

Cerecor Inc. (CERC) has completed patient enrolment in its phase II clinical trial of CERC-501 for smoking cessation. The company expects to report top-line data from this trial in the beginning of December 2016.

from RTT - Biotech http://ift.tt/2crCvLB
via IFTTT